Pune– Mylab Discovery Solutions, India’s leading biotechnology company, and Portland, OR-based Hemex Health, a medical diagnostic device company focused on creating diagnostics to transform frontline healthcare, announced the official launch of the Gazelle PathoCatch COVID-19 FIA test, their collaborative diagnostic solution for point-of-care (POC) testing in India. This portable, lightweight test detects all COVID-19 variants in 20 seconds with 99.4 percent accuracy compared to the gold standard, PCR. The diagnostic is currently under review with the US FDA for Emergency Use Authorization and will launch in Africa and the Middle East later this summer.
“Studies show that minimizing testing delay has the largest impact on reducing transmission,” said Hasmukh Rawal, Managing Director, Mylab Discovery Solutions. “We are excited to introduce this very affordable, highly accurate test into the market. It will be a great solution for hospitals, universities, and airports, where quick results are essential.”
The Gazelle PathoCatch test includes a fluorescent lateral flow immunoassay (FIA) and a reader that utilizes image-recognition software for detection of nucleocapsid protein from SARS-CoV-2. The reader uses AI imaging and signal-to-noise enhancement techniques to achieve near-PCR accuracy. Specimens are collected using a nasal swab.
Data from POC clinical studies with symptomatic and asymptomatic subjects, conducted in both Bellingham, WA and Pune and Mumbai, India, demonstrated 96.2 percent combined sensitivity, 99.7 percent combined specificity and 99.4 percent combined accuracy at detecting the virus in comparison to RT-PCR. Data from these studies is currently under peer review.
“The pandemic has driven home the need in all markets for faster, more accessible and more affordable POC diagnostics,” said Patti White, CEO and Co-Founder, Hemex Health. “Gazelle was positioned to help provide a solution to the testing effort with its fast and detailed analyses. Using our AI and FIA technologies, we discovered we could find even the smallest trace of virus in a sample. We are excited to bring this product to the consumer market to aid in the pandemic fight and be there ahead of the next wave.”
Discussion about this post